Literature DB >> 7979582

Bone mineral density in nonsteroid treated early rheumatoid arthritis.

B D Shenstone1, A Mahmoud, R Woodward, D Elvins, R Palmer, F Ring, A K Bhalla.   

Abstract

OBJECTIVES: To determine whether significant reduction in bone mass is detectable in early disease in patients with rheumatoid arthritis (RA) and to examine the possible influences of disease activity and physical disability on bone mineral density (BMD) of the lumbar spine (LS) and femoral neck (FN).
METHODS: LS and FN BMD values were measured and Z scores determined in a cross-sectional study of 104 patients with RA of less than five years duration. BMD values were also compared between a subgroup of 64 patients and a normal control group matched for age, sex, menopausal status and body mass. BMD values and Z scores were correlated with disease activity, measured by the Stoke Index, disability, measured by HAQ score, and disease duration.
RESULTS: Premenopausal female patients with RA had significantly reduced mean FN Z scores (-0.62, 95% CI -0.30 to -0.94) which correlated with HAQ scores (Rs 0.358, p = 0.05) and age (Rs 0.397, p = 0.03). There were no significant changes of BMD in males or postmenopausal females. Disease duration and disease activity did not correlate with BMD changes.
CONCLUSION: BMD is reduced in premenopausal female patients with early RA possibly related to the attainment of peak bone mass. No significant reduction of BMD was found in males or postmenopausal females with early disease. Physical disability but not disease activity appears to play a role in the reduction of FN bone mass.

Entities:  

Mesh:

Year:  1994        PMID: 7979582      PMCID: PMC1005436          DOI: 10.1136/ard.53.10.681

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Axial bone density in rheumatoid arthritis: comparison of dual-energy projection radiography and dual-photon absorptiometry.

Authors:  M O'Malley; A J Kenrick; D J Sartoris; A M Hochberg; M H Weisman; E Ramos; N Zvaifler; D Resnick
Journal:  Radiology       Date:  1989-02       Impact factor: 11.105

2.  Bone mineral density in Australia compared with the United States.

Authors:  N A Pocock; J A Eisman; R B Mazess; P N Sambrook; M G Yeates; J Freund
Journal:  J Bone Miner Res       Date:  1988-12       Impact factor: 6.741

3.  Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis.

Authors:  J R Kirwan; J S Reeback
Journal:  Br J Rheumatol       Date:  1986-05

4.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

Authors:  D M Ritchie; J A Boyle; J M McInnes; M K Jasani; T G Dalakos; P Grieveson; W W Buchanan
Journal:  Q J Med       Date:  1968-07

5.  Mineral metabolism and bone mineral content in rheumatoid arthritis. Effect of corticosteroids.

Authors:  A D'Angelo; A Fabris; L Sartori; L Malvasi; P Travaglia; P F Gambari; S Todesco
Journal:  Clin Exp Rheumatol       Date:  1985 Apr-Jun       Impact factor: 4.473

6.  Spinal trabecular bone mineral content in patients with non-steroid treated rheumatoid arthritis.

Authors:  J E Compston; E O Crawley; C Evans; M M O'Sullivan
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

7.  Generalized osteoporosis in non-steroid treated rheumatoid arthritis.

Authors:  M Magaro; A Tricerri; D Piane; A Zoli; F Serra; L Altomonte; L Mirone
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

8.  Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis?

Authors:  O S Als; A Gotfredsen; B J Riis; C Christiansen
Journal:  Ann Rheum Dis       Date:  1985-06       Impact factor: 19.103

9.  Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy.

Authors:  R F Laan; P L van Riel; L J van Erning; J A Lemmens; S H Ruijs; L B van de Putte
Journal:  Br J Rheumatol       Date:  1992-02

10.  Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity.

Authors:  R F Laan; W C Buijs; A L Verbeek; M P Draad; F H Corstens; L B van de Putte; P L van Riel
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

View more
  6 in total

1.  Are young women and men with rheumatoid arthritis at risk for fragility fractures? A population-based study.

Authors:  Shreyasee Amin; Sherine E Gabriel; Sara J Achenbach; Elizabeth J Atkinson; L Joseph Melton
Journal:  J Rheumatol       Date:  2013-08-15       Impact factor: 4.666

2.  Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis.

Authors:  M Güler-Yüksel; J Bijsterbosch; Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; H K Ronday; A J Peeters; J M de Jonge-Bok; F C Breedveld; B A C Dijkmans; C F Allaart; W F Lems
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

3.  Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis.

Authors:  Peter Oelzner; Antje Schwabe; Gabriele Lehmann; Thorsten Eidner; Sybille Franke; Gunter Wolf; Gert Hein
Journal:  Rheumatol Int       Date:  2008-04-30       Impact factor: 2.631

4.  Bone loss. Quantitative imaging techniques for assessing bone mass in rheumatoid arthritis.

Authors:  C F Njeh; H K Genant
Journal:  Arthritis Res       Date:  2000-08-03

5.  Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs.

Authors:  Behzad Heidari; Mahmoud Monadi; Mohammad Ali Ghazi Mirsaed
Journal:  Caspian J Intern Med       Date:  2012

6.  Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.

Authors:  Serena Bugatti; Laura Bogliolo; Barbara Vitolo; Antonio Manzo; Carlomaurizio Montecucco; Roberto Caporali
Journal:  Arthritis Res Ther       Date:  2016-10-06       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.